

#### Brief Description of the Drawings

- Figure 1 shows the anti-OspA responses in mice of Example 2.
- Figure 2 shows the LA2 titres in mice of Example 2.
- Figure 3 shows anti-OspA responses in mice of Example 3.
- Figure 4 shows LA2 titres in mice of Example 3.
- Figure 5 shows Anti-OspA antibody titres in mice of Example 4.
- Figure 6 shows LA2 titres in mice of Example 4.
- Figure 7 shows anti-TT immunoglobulin responses as measured by ELISA of Example 5.
- Figure 8 shows anti-FHA immunoglobulin responses as measured by ELISA of Example 5.
- Figure 9 shows anti-OspA ELISA titres in AGM's of Example 6.
- Figure 10 shows LA2 titres in AGM's of Example 6.
- Figure 11 shows intranasal priming and boosting of AGM's, anti-OspA ELISA responses of Example 7.
- Figure 12 shows intranasal priming and boosting of African Green Monkeys with POE and CpG vaccine formulations (of Example 8) and nasal induction of systemic Abs to lipo OspA in monkeys.
- Figure 13 shows intranasal priming and boosting of African Green Monkeys with POE and CpG vaccine formulations (of Example 8) and induction of nasal IgA to lipo OspA in monkeys.
- Figure 14 shows intranasal boosting of mice with POE-9LE and CpG vaccine formulations (of Example 9) and nasal boosting of serum IgG.
- Figure 15 shows intranasal boosting of mice with POE-9LE and CpG vaccine formulations (of Example 9) and nasal boosting of serum LA2 Abs.
- Figure 16 shows serum IgG responses to Lipo-OspA in mice of Example 10.
- Figure 17 shows serum LA2 titres in mice of Example 10.
- Figure 18 shows serum IgG response to influenza virus A/Singapore/6/86 in mice of Example 11.
- Figure 19 shows serum IgG Abs to influenza virus A/Beijing/262/95 in Africa Green monkeys of Example 12.
- Figure 20 shows serum IgG response to PS14 in mice of Example 13.
- Figure 21 shows serum IgG response to PS19 in mice of Example 13.
- Figure 22 shows serum IgG responses to Lipo-OspA in mice of Example 14.
- Figure 23 shows serum LA2 titers in mice of Example 14.